ClearPoint Neuro, Inc. (CLPT)
NASDAQ: CLPT · IEX Real-Time Price · USD
5.30
-0.03 (-0.56%)
Jul 2, 2024, 4:00 PM EDT - Market closed
ClearPoint Neuro Revenue
ClearPoint Neuro had revenue of $26.16M in the twelve months ending March 31, 2024, with 24.86% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $7.64M with 40.60% year-over-year growth. In the year 2023, ClearPoint Neuro had annual revenue of $23.96M with 16.56% growth.
Revenue (ttm)
$26.16M
Revenue Growth
+24.86%
P/S Ratio
5.56
Revenue / Employee
$244,495
Employees
107
Market Cap
145.33M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 23.96M | 3.40M | 16.56% |
Dec 31, 2022 | 20.55M | 4.25M | 26.09% |
Dec 31, 2021 | 16.30M | 3.47M | 27.05% |
Dec 31, 2020 | 12.83M | 1.61M | 14.37% |
Dec 31, 2019 | 11.22M | 3.86M | 52.54% |
Dec 31, 2018 | 7.35M | -26.26K | -0.36% |
Dec 31, 2017 | 7.38M | 1.63M | 28.35% |
Dec 31, 2016 | 5.75M | 1.16M | 25.15% |
Dec 31, 2015 | 4.59M | 989.71K | 27.46% |
Dec 31, 2014 | 3.60M | -326.09K | -8.30% |
Dec 31, 2013 | 3.93M | -1.13M | -22.29% |
Dec 31, 2012 | 5.06M | 1.24M | 32.48% |
Dec 31, 2011 | 3.82M | 1.15M | 43.03% |
Dec 31, 2010 | 2.67M | 69.45K | 2.67% |
Dec 31, 2009 | 2.60M | 650.00K | 33.33% |
Dec 31, 2008 | 1.95M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
TruBridge | 336.45M |
InfuSystem Holdings | 127.41M |
Rigel Pharmaceuticals | 120.35M |
Caribou Biosciences | 33.40M |
TriSalus Life Sciences | 21.98M |
MediWound | 19.85M |
CLPT News
- 12 days ago - ClearPoint Neuro Congratulates Partner Aspen Neuroscience on Use of the ClearPoint® Navigation System for All Enrolled Patients in ASPIRO Clinical Trial - GlobeNewsWire
- 12 days ago - Parkinson's Disease Clinical Trial Uses Intraoperative MRI to Guide Precision Implantation of Patients' Own Autologous Replacement Neurons - PRNewsWire
- 4 weeks ago - ClearPoint Neuro Announces Full Market Release of SmartFrame OR™ and ClearPoint PRISM® 3T Laser Therapy System - GlobeNewsWire
- 2 months ago - SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT) - PRNewsWire
- 2 months ago - ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations - GlobeNewsWire
- 3 months ago - ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency - GlobeNewsWire
- 4 months ago - ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results - GlobeNewsWire
- 4 months ago - ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024 - GlobeNewsWire